COVID-19 vaccine-elicited immune mediators and their contribution to protective immunity
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20260725Keywords:
SARS-CoV2, Vaccine, Humoral immunity, Cytokines, Cellular immunityAbstract
SARS-CoV-2, a highly transmissible virus triggered the COVID-19 pandemic inflicting devastating impact on public health and global economy; thus, the development of a vaccine was deemed the most efficient strategy. The immune system is a network of specialized cell types that interacts with cytokines to orchestrate protective responses. Until recently, investigators only evaluated vaccine efficacy with an emphasis on secreted antibodies, despite advancements in vaccinology no well-confirmed immunological correlates of vaccine-induced protection have been recognized. Technological and conceptual advances in cell-mediated immunology have resulted in numerous novel immunological signals, which could function as classifiers for vaccine-induced protection. Cytokine responses are essential for triggering and retaining humoral responses, which could potentially impact vaccination efficiency, thus, profiling might uncover vital information on the indicators of vaccine response and long-term protective variables. This integrated immunological approach to vaccine response provides a broader perspective and ensures an improved comprehension of the pathways and mechanisms involved. Here we aim to summarize the mechanism of action of the different vaccines developed and examine several immunological mediators associated with SARS-CoV2 immunization. We also provide insights, on new possibilities correlating with vaccine-induced immune responses and their effectiveness in defining protective immunity.
Metrics
References
Li Q, Wang Y, Sun Q, Knopf J, Herrmann M, Lin L, et al. Immune response in COVID-19: what is next?. Cell Death Differ. 2022;29(6):1107-22. DOI: https://doi.org/10.1038/s41418-022-01015-x
Ruytinx P, Vandormael P, Fraussen J, Pieters Z, Thonissen S, Hellings N, et al. Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort. Sci Rep. 2023;13(1):19322. DOI: https://doi.org/10.1038/s41598-023-46421-4
Queiroz MAF, Neves PFMD, Lima SS, Lopes JDC, Torres MKDS, Vallinoto IMVC, et al. Cytokine Profiles Associated with Acute COVID-19 and Long COVID-19 Syndrome. Front Cell Infect Microbiol. 2022;12:922422. DOI: https://doi.org/10.3389/fcimb.2022.922422
Worldometer. Real Time World Statistics. Available at https://www.worldometers.info/ coronavirus/. Accessed on 21 December 2025.
Lam ICH, Zhang R, Man KKC, Wong CKH, Chui CSL, Lai FTT, et al. Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection. Nat Commun. 2024;15(1):1716. DOI: https://doi.org/10.1038/s41467-024-45953-1
World Health Organization. Covid-19 advice for the public: Getting Vaccinated. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice. Accessed on 21 December 2025.
Simon WL, Salk HM, Ovsyannikova IG, Kennedy RB, Poland GA. Cytokine production associated with smallpox vaccine responses. Immunotherapy. 2014;6(10):1097-112. DOI: https://doi.org/10.2217/imt.14.72
Talaat KR, Halsey NA, Cox AB, Coles CL, Durbin AP, Ramakrishnan A, et al. Rapid changes in serum cytokines and chemokines in response to inactivated influenza vaccination. Influenza Other Respir Viruses. 2018;12(2):202-10. DOI: https://doi.org/10.1111/irv.12509
Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, et al. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci. 2022;29(1):82. DOI: https://doi.org/10.1186/s12929-022-00853-8
Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infect Drug Resist. 2021;14:3459-76. DOI: https://doi.org/10.2147/IDR.S315727
Ahmed TI, Rishi S, Irshad S, Aggarwal J, Happa K, Mansoor S. Inactivated vaccine Covaxin/BBV152: A systematic review. Front Immunol. 2022;13:863162. DOI: https://doi.org/10.3389/fimmu.2022.863162
Talukder A, Kalita C, Neog N, Goswami C, Sarma MK, Hazarika I. A comparative analysis on the safety and efficacy of Covaxin versus other vaccines against COVID-19: a review. Z Naturforsch C J Biosci. 2022;77(8):351-62. DOI: https://doi.org/10.1515/znc-2021-0301
Patel R, Kaki M, Potluri VS, Kahar P, Khanna D. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna and Johnson and Johnson. Hum Vaccin Immunother. 2022;18(1):2002083. DOI: https://doi.org/10.1080/21645515.2021.2002083
Bian L, Liu J, Gao F, Gao Q, He Q, Mao Q, et al. Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. Hum Vaccin Immunother. 2022;18(5):2057161. DOI: https://doi.org/10.1080/21645515.2022.2057161
Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Viruses. 2023;15(1):167. DOI: https://doi.org/10.3390/v15010167
Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021;385(25):2348-60. DOI: https://doi.org/10.1056/NEJMoa2105290
Shen CF, Yen CL, Fu YC, Cheng CM, Shen TC, Chang PD, et al. Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination. Front Immunol. 2022;13:807454. DOI: https://doi.org/10.3389/fimmu.2022.807454
Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, et al. Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees. Clin Infect Dis. 2022;74(2):366-8. DOI: https://doi.org/10.1093/cid/ciab411
Tulimilli SV, Dallavalasa S, Basavaraju CG, Kumar Rao V, Chikkahonnaiah P, Madhunapantula SV, et al. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vaccines (Basel). 2022;10(10):1751. DOI: https://doi.org/10.3390/vaccines10101751
Shkoda AS, Gushchin VA, Ogarkova DA, Stavitskaya SV, Orlova OE, Kuznetsova NA, et al. Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. Vaccines (Basel). 2022;10(6):938. DOI: https://doi.org/10.3390/vaccines10060938
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15. DOI: https://doi.org/10.1056/NEJMoa2034577
Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021;27:1614-21. DOI: https://doi.org/10.1038/s41591-021-01446-y
Pajon R, Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, et al. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. N Engl J Med. 2022;386(11):1088-91. DOI: https://doi.org/10.1056/NEJMc2119912
Gram MA, Emborg HD, Schelde AB, Friis NU, Nielsen KF, Moustsen-Helms IR, et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. PLoS Med. 2022;19(9):e1003992. DOI: https://doi.org/10.1371/journal.pmed.1003992
Muik A, Lui BG, Wallisch AK, Bacher M, Mühl J, Reinholz J, et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science. 2022;375(6581):678-80. DOI: https://doi.org/10.1126/science.abn7591
Lapa D, Grousova DM, Matusali G, Meschi S, Colavita F, Bettini A, et al. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals. Vaccines (Basel). 2022;10(5):817. DOI: https://doi.org/10.3390/vaccines10050817
Jahan N, Rahman FI, Saha P, Ether SA, Roknuzzaman A, Sarker R, et al. Side Effects Following Administration of the First Dose of Oxford-AstraZeneca's Covishield Vaccine in Bangladesh: A Cross-Sectional Study. Infect Dis Rep. 2021;13(4):888-901. DOI: https://doi.org/10.3390/idr13040080
Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni T. S, Esfandiari K, Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. Immunopathologia Persa. 2021;7(2):1-5. DOI: https://doi.org/10.34172/ipp.2021.31
Meo SA, ElToukhy RA, Meo AS, Klonoff DC. Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study. Vaccines (Basel). 2023;11(4):826. DOI: https://doi.org/10.3390/vaccines11040826
Abukhalil AD, Shatat SS, Abushehadeh RR, Al-Shami N, Naseef HA, Rabba A. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community. BMC Infect Dis. 2023;23(1):5. DOI: https://doi.org/10.1186/s12879-022-07974-3
Contractor A, Shivaprakash S, Tiwari A, Setia MS, Gianchandani T. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis. PLoS One. 2022;17(10):e0276759. DOI: https://doi.org/10.1371/journal.pone.0276759
Đurić-Petković D, Šuljagić V, Begović-Kuprešanin V, Rančić N, Nikolić V. Vaccine Effectiveness against SARS-CoV-2 Infection during the Circulation of Alpha, Delta, or Omicron Variants: A Retrospective Cohort Study in a Tertiary Hospital in Serbia. Vaccines (Basel). 2024;12(2):211. DOI: https://doi.org/10.3390/vaccines12020211
Haque MA, Tanbir M, Ahamed B, Hossain MJ, Roy A, Shahriar M, et al. Comparative Performance Evaluation of Personal Protective Measures and Antiviral Agents Against SARS-CoV-2 Variants: A Narrative Review. Clin Pathol. 2023;16:2632010X231161222. DOI: https://doi.org/10.1177/2632010X231161222
Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat Microbiol. 2022;7(3):379-85. DOI: https://doi.org/10.1038/s41564-021-01053-0
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022;386:1532-46. DOI: https://doi.org/10.1056/NEJMoa2119451
Naito T, Tsuchida N, Kusunoki S, Kaneko Y, Tobita M, Hori S, et al. Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study. Expert Rev Vaccines. 2022;21(9):1319-29. DOI: https://doi.org/10.1080/14760584.2022.2093722
Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27(9):1525-9. DOI: https://doi.org/10.1038/s41591-021-01449-9
Goda V, Kriván G, Kulcsár A, Gönczi M, Tasnády S, Matula Z, et al. Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency. Front Immunol. 2022;13:907125. DOI: https://doi.org/10.3389/fimmu.2022.907125
Klemis V, Schmidt T, Schub D, Mihm J, Marx S, Abu-Omar A, et al. Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. Nat Commun. 2022;13:4710. DOI: https://doi.org/10.1038/s41467-022-32321-0
Kaku CI, Champney ER, Normark J, Garcia M, Johnson CE, Ahlm C, et al. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination. Science. 2022;375(6584):1041-7. DOI: https://doi.org/10.1126/science.abn2688
Laham G, Martínez AP, Rojas Gimenez W, Amaya L, Abib A, Echegoyen N, et al. Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients. J Nephrol. 2023;36(3):861-72. DOI: https://doi.org/10.1007/s40620-022-01446-2
Ndzouboukou JB, Kamara AA, Ullah N, Lei Q, Fan XL. A Meta-Analysis on the Immunogenicity of Homologous versus Heterologous Immunization Regimens against SARS-CoV-2 Beta, Delta, and Omicron BA.1 VoCs in Healthy Adults. J Microbiol Biotechnol. 2025;35:e2411059. DOI: https://doi.org/10.4014/jmb.2411.11059
Sanin KI, Khanam M, Sharaque AR, Elahi M, Roy BR, Hasan MK, et al. Comparing Antibody Responses to Homologous vs. Heterologous COVID-19 Vaccination: A Cross-Sectional Analysis in an Urban Bangladeshi Population. Vaccines (Basel). 2025;13(1):67. DOI: https://doi.org/10.3390/vaccines13010067
Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27:270-8. DOI: https://doi.org/10.1038/s41591-020-01194-5
Heo JY, Seo YB, Kim EJ, Lee J, Kim YR, Yoon JG, et al. COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19. Front Immunol. 2022;13:975363. DOI: https://doi.org/10.3389/fimmu.2022.975363
Tripathy AS, Singh D, Trimbake D, Salwe S, Tripathy S, Kakrani A, et al. Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India. Hum Vaccin Immunother. 2024;20(1):2410579. DOI: https://doi.org/10.1080/21645515.2024.2410579
Rakshit S, Adiga V, Ahmed A, Parthiban C, Chetan Kumar N, Dwarkanath P, et al. Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults. Front Immunol. 2022;13:985938. DOI: https://doi.org/10.3389/fimmu.2022.985938
Martynova E, Hamza S, Garanina EE, Kabwe E, Markelova M, Shakirova V, et al. Long Term Immune Response Produced by the SputnikV Vaccine. Int J Mol Sci. 2021;22(20):11211. DOI: https://doi.org/10.3390/ijms222011211
Kumar NP, Banurekha VV, C P GK, Nancy A, Padmapriyadarsini C, Mary AS, et al. Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses. Front Immunol. 2021;12:752397. DOI: https://doi.org/10.3389/fimmu.2021.752397
Sun Y, Kang H, Zhao Y, Cui K, Wu X, Huang S, et al. Immune response after vaccination using inactivated vaccine for coronavirus disease 2019. Chin Med J (Engl). 2023;136(12):1497-9. DOI: https://doi.org/10.1097/CM9.0000000000002707
Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595(7868):572-7. DOI: https://doi.org/10.1038/s41586-021-03653-6
Bergamaschi C, Terpos E, Rosati M, Angel M, Bear J, Stellas D, et al. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021;36(6):109504. DOI: https://doi.org/10.1016/j.celrep.2021.109504
Rosati M, Terpos E, Homan P, Bergamaschi C, Karaliota S, Ntanasis-Stathopoulos I, et al. Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations. Front Immunol. 2023;14:1292568. DOI: https://doi.org/10.3389/fimmu.2023.1292568
Föhse K, Geckin B, Zoodsma M, Kilic G, Liu Z, Röring RJ, et al. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses. Clin Immunol. 2023;255:109762. DOI: https://doi.org/10.1016/j.clim.2023.109762
Nakayama T, Sawada A, Ito T. Comparison of cytokine production in mice inoculated with messenger RNA vaccines BNT162b2 and mRNA-1273. Microbiol Immunol. 2023;67(3):120-8. DOI: https://doi.org/10.1111/1348-0421.13043
Konnova A, De Winter FHR, Gupta A, Verbruggen L, Hotterbeekx A, Berkell M, et al. Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors. Front Immunol. 2022;13:1062136. DOI: https://doi.org/10.3389/fimmu.2022.1062136
Ramos-Martinez E, Falfán-Valencia R, Pérez-Rubio G, Andrade WA, Rojas-Serrano J, Ambrocio-Ortiz E, et al. Effect of BCG Revaccination on Occupationally Exposed Medical Personnel Vaccinated against SARS-CoV-2. Cells. 2021;10(11):3179. DOI: https://doi.org/10.3390/cells10113179
Jiang M, Väisänen E, Kolehmainen P, Huttunen M, Ylä-Herttuala S, Meri S, et al. COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs. Vaccine. 2023;41(26):3813-23. DOI: https://doi.org/10.1016/j.vaccine.2023.04.049
Amanah A, Ariyanto IA, Bela B, Primanagara R, Sudarmono P. Evaluation of the Effect of mRNA and Inactivated SARS-CoV-2 Vaccines on the Levels of Cytokines IL-2, IFN-γ, and Anti-RBD Spike SARS-CoV-2 Antibodies in People Living with HIV (PLHIV). Biomedicines. 2024;12(9):2115. DOI: https://doi.org/10.3390/biomedicines12092115
Isogawa M, Onodera T, Ainai A, Kotaki R, Kanno T, Saito S, et al. Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens. Sci Rep. 2025;15(1):18684. DOI: https://doi.org/10.1038/s41598-025-00054-x
Downloads
Published
How to Cite
Issue
Section
